Buka Richard J, Roy Noémi, Nicolson Phillip Lr
Institute of Cardiovascular Sciences University of Birmingham Birmingham UK.
HaemSTAR Birmingham UK.
EJHaem. 2022 Dec 25;4(1):13-17. doi: 10.1002/jha2.623. eCollection 2023 Feb.
Crizanlizumab was recommended for use in patients with sickle cell disease in the UK in October 2021 and received widespread media coverage. Accuracy of reporting is paramount in building trust with this group of patients who are often wary of the medical profession. We carried out an analysis of internet-based news articles and applied a validated scoring system to assess quality. 21 articles from 19 media organisations were identified. 71% of articles stated unproven benefits of the drug and only 14% were of satisfactory quality. The former was largely due to quoting of two NHS England press releases. Overstating of drug efficacy may be detrimental to the need to address healthcare inequalities.
2021年10月，英国推荐将crizanlizumab用于镰状细胞病患者，该药物受到了媒体的广泛报道。对于这群常常对医疗行业持谨慎态度的患者而言，报道的准确性对于建立信任至关重要。我们对基于互联网的新闻文章进行了分析，并应用经过验证的评分系统来评估质量。我们识别出了来自19家媒体机构的21篇文章。71%的文章陈述了该药物未经证实的益处，只有14%的文章质量令人满意。前者很大程度上是由于引用了两份英国国家医疗服务体系（NHS）英格兰的新闻稿。夸大药物疗效可能不利于解决医疗保健不平等问题。
